| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis B virus | 4 | 2019 | 882 | 1.33 | Why? |
| Aircraft | 2 | 2020 | 498 | 1.22 | Why? |
| Hepacivirus | 4 | 2019 | 1509 | 1.21 | Why? |
| Liver Failure, Acute | 2 | 2019 | 279 | 1.19 | Why? |
| Thiocyanates | 1 | 2021 | 28 | 0.93 | Why? |
| Hepatitis B | 4 | 2019 | 888 | 0.91 | Why? |
| BK Virus | 2 | 2018 | 135 | 0.83 | Why? |
| Cadaver | 2 | 2021 | 626 | 0.81 | Why? |
| Guanidines | 2 | 2021 | 499 | 0.80 | Why? |
| Hepatitis B Antibodies | 2 | 2017 | 142 | 0.79 | Why? |
| Hepatitis C | 3 | 2019 | 1514 | 0.73 | Why? |
| Torque teno virus | 1 | 2018 | 73 | 0.70 | Why? |
| Caco-2 Cells | 11 | 2021 | 1236 | 0.70 | Why? |
| DNA Virus Infections | 1 | 2018 | 88 | 0.69 | Why? |
| Transfusion Reaction | 1 | 2020 | 245 | 0.69 | Why? |
| Polyomavirus Infections | 2 | 2018 | 156 | 0.69 | Why? |
| Trans-Activators | 1 | 2018 | 170 | 0.67 | Why? |
| Hepatitis B Core Antigens | 1 | 2017 | 76 | 0.67 | Why? |
| Lipoproteins | 1 | 2018 | 240 | 0.67 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.64 | Why? |
| Methylene Blue | 1 | 2018 | 175 | 0.63 | Why? |
| Cloning, Molecular | 1 | 2019 | 1036 | 0.58 | Why? |
| Carrier Proteins | 1 | 2018 | 513 | 0.58 | Why? |
| Allografts | 1 | 2018 | 761 | 0.57 | Why? |
| Blood Safety | 1 | 2020 | 459 | 0.57 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.56 | Why? |
| Virus Replication | 12 | 2021 | 14331 | 0.53 | Why? |
| Donor Selection | 1 | 2020 | 804 | 0.51 | Why? |
| Air Travel | 1 | 2020 | 585 | 0.51 | Why? |
| Virus Inactivation | 1 | 2021 | 1139 | 0.45 | Why? |
| Travel | 2 | 2020 | 7220 | 0.44 | Why? |
| DNA, Viral | 3 | 2018 | 2521 | 0.42 | Why? |
| Host-Pathogen Interactions | 9 | 2021 | 11041 | 0.39 | Why? |
| Anti-Infective Agents | 1 | 2021 | 1766 | 0.39 | Why? |
| Waste Water | 1 | 2020 | 2185 | 0.39 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.38 | Why? |
| Germany | 9 | 2021 | 9196 | 0.37 | Why? |
| Hepatitis Delta Virus | 2 | 2019 | 54 | 0.36 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.32 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.31 | Why? |
| High-Throughput Screening Assays | 3 | 2021 | 1783 | 0.31 | Why? |
| Drug Repositioning | 3 | 2021 | 5683 | 0.31 | Why? |
| Betacoronavirus | 15 | 2020 | 204454 | 0.28 | Why? |
| Antiviral Agents | 9 | 2021 | 41703 | 0.27 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.26 | Why? |
| RNA, Viral | 7 | 2021 | 32276 | 0.26 | Why? |
| Genome, Viral | 4 | 2020 | 13157 | 0.26 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.25 | Why? |
| Coronavirus Infections | 15 | 2020 | 253789 | 0.24 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.24 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.24 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.24 | Why? |
| Exhumation | 1 | 2021 | 11 | 0.23 | Why? |
| Papaverine | 1 | 2021 | 16 | 0.23 | Why? |
| Cetylpyridinium | 1 | 2021 | 52 | 0.23 | Why? |
| Mefloquine | 1 | 2021 | 39 | 0.23 | Why? |
| Receptors, Growth Factor | 1 | 2020 | 9 | 0.22 | Why? |
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 28 | 0.22 | Why? |
| Cell Line | 4 | 2021 | 12040 | 0.22 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.22 | Why? |
| Aprotinin | 1 | 2020 | 63 | 0.21 | Why? |
| Day Care, Medical | 1 | 2021 | 117 | 0.21 | Why? |
| Diagnostic Equipment | 1 | 2020 | 41 | 0.21 | Why? |
| Furans | 1 | 2021 | 156 | 0.21 | Why? |
| Humans | 58 | 2021 | 930598 | 0.21 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2020 | 13720 | 0.21 | Why? |
| Mitogen-Activated Protein Kinases | 1 | 2020 | 126 | 0.20 | Why? |
| Itraconazole | 1 | 2021 | 135 | 0.20 | Why? |
| Histamine Antagonists | 1 | 2021 | 203 | 0.20 | Why? |
| Hepatitis D, Chronic | 1 | 2019 | 16 | 0.20 | Why? |
| Claudin-1 | 1 | 2019 | 12 | 0.20 | Why? |
| Benzamidines | 1 | 2021 | 206 | 0.20 | Why? |
| Sequence Analysis, DNA | 2 | 2019 | 2830 | 0.19 | Why? |
| Cytosol | 1 | 2018 | 77 | 0.19 | Why? |
| Kidney Transplantation | 2 | 2018 | 5397 | 0.19 | Why? |
| Cold Ischemia | 1 | 2018 | 37 | 0.19 | Why? |
| Triazines | 1 | 2021 | 246 | 0.19 | Why? |
| Famotidine | 1 | 2021 | 136 | 0.19 | Why? |
| Cell Line, Tumor | 4 | 2021 | 3608 | 0.19 | Why? |
| Esters | 1 | 2021 | 300 | 0.19 | Why? |
| Toll-Like Receptor 3 | 1 | 2021 | 391 | 0.18 | Why? |
| Pyrroles | 1 | 2021 | 292 | 0.18 | Why? |
| Endoplasmic Reticulum | 1 | 2021 | 430 | 0.18 | Why? |
| Gene Library | 1 | 2019 | 234 | 0.18 | Why? |
| Transduction, Genetic | 1 | 2018 | 273 | 0.17 | Why? |
| Yellow fever virus | 1 | 2019 | 205 | 0.17 | Why? |
| Otorhinolaryngologic Diseases | 2 | 2021 | 491 | 0.17 | Why? |
| Protein Isoforms | 1 | 2018 | 347 | 0.17 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.17 | Why? |
| Mutant Proteins | 1 | 2018 | 328 | 0.17 | Why? |
| Scavenger Receptors, Class B | 1 | 2017 | 48 | 0.17 | Why? |
| RNA, Untranslated | 1 | 2018 | 140 | 0.17 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2019 | 170 | 0.16 | Why? |
| Hepatitis D | 1 | 2017 | 48 | 0.16 | Why? |
| Replicon | 1 | 2018 | 232 | 0.16 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3633 | 0.16 | Why? |
| DNA, Complementary | 1 | 2019 | 568 | 0.16 | Why? |
| Yellow Fever | 1 | 2019 | 231 | 0.16 | Why? |
| Primates | 1 | 2019 | 584 | 0.16 | Why? |
| Mosquito Vectors | 1 | 2019 | 351 | 0.16 | Why? |
| Hepatitis Antibodies | 1 | 2017 | 100 | 0.16 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.15 | Why? |
| Mutation, Missense | 1 | 2021 | 863 | 0.15 | Why? |
| Acute-On-Chronic Liver Failure | 1 | 2019 | 237 | 0.15 | Why? |
| Viral Load | 5 | 2020 | 15850 | 0.15 | Why? |
| Pharynx | 2 | 2020 | 1544 | 0.15 | Why? |
| Containment of Biohazards | 1 | 2021 | 762 | 0.14 | Why? |
| Cyclophilin A | 1 | 2015 | 90 | 0.14 | Why? |
| Cell Survival | 1 | 2020 | 1581 | 0.14 | Why? |
| Amino Acid Substitution | 1 | 2021 | 1706 | 0.14 | Why? |
| Cell Culture Techniques | 1 | 2019 | 704 | 0.13 | Why? |
| Myocytes, Cardiac | 1 | 2020 | 804 | 0.13 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.13 | Why? |
| Pandemics | 16 | 2021 | 389249 | 0.13 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.13 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.12 | Why? |
| Molecular Diagnostic Techniques | 2 | 2020 | 4239 | 0.12 | Why? |
| Vero Cells | 4 | 2021 | 14117 | 0.12 | Why? |
| Drug Evaluation, Preclinical | 2 | 2021 | 3347 | 0.12 | Why? |
| Nucleic Acid Amplification Techniques | 3 | 2021 | 3388 | 0.12 | Why? |
| Molecular Targeted Therapy | 1 | 2020 | 1579 | 0.11 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.11 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.11 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.10 | Why? |
| Polymorphism, Single Nucleotide | 3 | 2018 | 3607 | 0.10 | Why? |
| Apoptosis | 1 | 2020 | 2335 | 0.10 | Why? |
| Mutation | 3 | 2019 | 12376 | 0.10 | Why? |
| Orthomyxoviridae | 1 | 2019 | 1168 | 0.10 | Why? |
| Clinical Laboratory Techniques | 4 | 2021 | 23402 | 0.10 | Why? |
| Adult | 11 | 2021 | 244371 | 0.10 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.10 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.10 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.10 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.10 | Why? |
| Proteomics | 1 | 2020 | 2481 | 0.09 | Why? |
| Ambulatory Care Facilities | 1 | 2020 | 2063 | 0.09 | Why? |
| Interferon Regulatory Factor-3 | 2 | 2021 | 379 | 0.09 | Why? |
| Cities | 1 | 2020 | 4937 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Aged | 8 | 2021 | 215776 | 0.09 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 11367 | 0.08 | Why? |
| Female | 12 | 2021 | 380317 | 0.08 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.08 | Why? |
| Male | 11 | 2021 | 367725 | 0.08 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.08 | Why? |
| Coronavirus 229E, Human | 1 | 2015 | 1241 | 0.08 | Why? |
| Receptors, Virus | 2 | 2021 | 5659 | 0.08 | Why? |
| Specimen Handling | 2 | 2021 | 6190 | 0.08 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Genetic Variation | 2 | 2017 | 3919 | 0.08 | Why? |
| Antigens, Viral | 2 | 2020 | 6298 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.08 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.07 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.07 | Why? |
| Virus Internalization | 3 | 2019 | 7921 | 0.07 | Why? |
| Transplant Recipients | 2 | 2018 | 4982 | 0.07 | Why? |
| Pediatrics | 1 | 2021 | 2969 | 0.07 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.07 | Why? |
| RNA, Messenger | 1 | 2019 | 5131 | 0.07 | Why? |
| Animals | 7 | 2021 | 78931 | 0.07 | Why? |
| NF-kappa B | 2 | 2021 | 1301 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Child | 3 | 2021 | 70012 | 0.06 | Why? |
| Calnexin | 1 | 2021 | 24 | 0.06 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2021 | 9659 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.06 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.06 | Why? |
| GTP Phosphohydrolases | 1 | 2021 | 89 | 0.06 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.05 | Why? |
| Raloxifene Hydrochloride | 1 | 2021 | 91 | 0.05 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.05 | Why? |
| Nelfinavir | 1 | 2021 | 187 | 0.05 | Why? |
| Knowledge Bases | 1 | 2021 | 113 | 0.05 | Why? |
| Deubiquitinating Enzymes | 1 | 2020 | 55 | 0.05 | Why? |
| Proteostasis | 1 | 2020 | 90 | 0.05 | Why? |
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 76 | 0.05 | Why? |
| Cathepsins | 1 | 2020 | 204 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.05 | Why? |
| Signal Transduction | 3 | 2021 | 7207 | 0.05 | Why? |
| RNA Splicing | 1 | 2020 | 119 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Cells, Cultured | 2 | 2021 | 5835 | 0.05 | Why? |
| Cyclosporins | 1 | 2018 | 16 | 0.05 | Why? |
| Ubiquitins | 1 | 2020 | 202 | 0.05 | Why? |
| Minor Histocompatibility Antigens | 1 | 2019 | 56 | 0.05 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2020 | 393 | 0.05 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2021 | 253 | 0.05 | Why? |
| Chemokine CCL2 | 1 | 2021 | 389 | 0.05 | Why? |
| Ubiquitination | 1 | 2020 | 343 | 0.05 | Why? |
| Infant | 1 | 2021 | 30274 | 0.05 | Why? |
| Interleukin-12 | 1 | 2019 | 156 | 0.05 | Why? |
| Hep G2 Cells | 1 | 2019 | 391 | 0.04 | Why? |
| Carbon | 1 | 2020 | 269 | 0.04 | Why? |
| Drug Synergism | 1 | 2021 | 833 | 0.04 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2020 | 424 | 0.04 | Why? |
| RNA, Catalytic | 1 | 2017 | 15 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Yellow Fever Vaccine | 1 | 2019 | 198 | 0.04 | Why? |
| Tumor Virus Infections | 1 | 2018 | 127 | 0.04 | Why? |
| HeLa Cells | 1 | 2021 | 1303 | 0.04 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.04 | Why? |
| Benzazepines | 1 | 2017 | 49 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Adenosine | 1 | 2021 | 509 | 0.04 | Why? |
| Interleukin-18 | 1 | 2019 | 328 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2021 | 1132 | 0.04 | Why? |
| Phosphorylation | 1 | 2020 | 1060 | 0.04 | Why? |
| Serine Proteinase Inhibitors | 1 | 2020 | 341 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.04 | Why? |
| HEK293 Cells | 2 | 2021 | 8394 | 0.04 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.04 | Why? |
| Protein-Tyrosine Kinases | 1 | 2017 | 158 | 0.04 | Why? |
| Protein Biosynthesis | 1 | 2020 | 653 | 0.04 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.04 | Why? |
| Costs and Cost Analysis | 1 | 2020 | 694 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.04 | Why? |
| A549 Cells | 1 | 2021 | 2066 | 0.04 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.04 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 7868 | 0.04 | Why? |
| Neglected Diseases | 1 | 2019 | 381 | 0.04 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.03 | Why? |
| Automation | 1 | 2017 | 429 | 0.03 | Why? |
| Histocompatibility Antigens Class I | 1 | 2019 | 624 | 0.03 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Hepatocytes | 1 | 2017 | 549 | 0.03 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2019 | 760 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2018 | 925 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Viral Matrix Proteins | 1 | 2020 | 1243 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Open Reading Frames | 1 | 2018 | 1898 | 0.03 | Why? |
| Viral Tropism | 1 | 2019 | 1329 | 0.03 | Why? |
| Mice | 2 | 2021 | 21357 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.03 | Why? |
| Mice, Inbred BALB C | 1 | 2021 | 5814 | 0.03 | Why? |
| CRISPR-Cas Systems | 1 | 2019 | 1397 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Proteome | 1 | 2020 | 1812 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Patient Care | 1 | 2020 | 1664 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Binding Sites | 1 | 2021 | 6201 | 0.02 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.02 | Why? |
| Epithelial Cells | 1 | 2020 | 3508 | 0.02 | Why? |
| Interferons | 1 | 2020 | 2885 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.02 | Why? |
| Laboratories | 1 | 2020 | 2858 | 0.02 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2021 | 7268 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2020 | 4155 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2019 | 1810 | 0.02 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.02 | Why? |
| Computational Biology | 1 | 2021 | 4514 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2021 | 6902 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2017 | 3539 | 0.02 | Why? |
| Liver | 1 | 2019 | 4007 | 0.02 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |